Insmed Incorporated (INSM)
USD 65.88
(-4.77%)
USD 65.88
(-4.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 949.26 Million USD | 37.74% |
| 2022 | 668.35 Million USD | 30.52% |
| 2021 | 512.06 Million USD | 31.38% |
| 2020 | 389.77 Million USD | 12.16% |
| 2019 | 347.5 Million USD | 10.41% |
| 2018 | 314.75 Million USD | 66.6% |
| 2017 | 188.92 Million USD | 8.95% |
| 2016 | 173.4 Million USD | 47.58% |
| 2015 | 117.49 Million USD | 34.49% |
| 2014 | 87.36 Million USD | 31.35% |
| 2013 | 66.51 Million USD | 56.73% |
| 2012 | 42.43 Million USD | 5.71% |
| 2011 | 40.14 Million USD | 167.41% |
| 2010 | 15.01 Million USD | -21.18% |
| 2009 | 19.04 Million USD | -27.05% |
| 2008 | 26.11 Million USD | -4.68% |
| 2007 | 27.39 Million USD | -49.16% |
| 2006 | 53.87 Million USD | 95.44% |
| 2005 | 27.56 Million USD | 0.01% |
| 2004 | 27.56 Million USD | 156.73% |
| 2003 | 10.73 Million USD | -70.54% |
| 2002 | 36.44 Million USD | -9.97% |
| 2001 | 40.48 Million USD | 29.91% |
| 2000 | 31.16 Million USD | 250.91% |
| 1999 | 8.87 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 253.31 Million USD | 18.27% |
| 2024 Q3 | 285.68 Million USD | 12.78% |
| 2024 Q1 | 214.18 Million USD | -5.99% |
| 2023 Q4 | 227.82 Million USD | 13.32% |
| 2023 Q1 | 209.04 Million USD | 4.78% |
| 2023 Q2 | 282.66 Million USD | 35.22% |
| 2023 Q3 | 201.03 Million USD | -28.88% |
| 2023 FY | 920.56 Million USD | 37.74% |
| 2022 Q2 | 137.14 Million USD | -3.67% |
| 2022 Q4 | 199.5 Million USD | 9.65% |
| 2022 Q3 | 181.95 Million USD | 32.68% |
| 2022 FY | 668.35 Million USD | 30.52% |
| 2022 Q1 | 142.36 Million USD | -0.36% |
| 2021 Q4 | 142.88 Million USD | 8.33% |
| 2021 Q2 | 123.09 Million USD | 7.79% |
| 2021 Q1 | 114.2 Million USD | -8.7% |
| 2021 FY | 512.06 Million USD | 31.38% |
| 2021 Q3 | 131.89 Million USD | 7.15% |
| 2020 Q4 | 125.09 Million USD | 40.17% |
| 2020 Q1 | 88.77 Million USD | 5.58% |
| 2020 FY | 389.77 Million USD | 12.16% |
| 2020 Q2 | 86.65 Million USD | -2.39% |
| 2020 Q3 | 89.24 Million USD | 2.98% |
| 2019 FY | 347.5 Million USD | 10.41% |
| 2019 Q3 | 88.93 Million USD | 1.97% |
| 2019 Q4 | 84.08 Million USD | -5.46% |
| 2019 Q1 | 87.26 Million USD | -8.28% |
| 2019 Q2 | 87.21 Million USD | -0.05% |
| 2018 Q1 | 62.75 Million USD | -3.98% |
| 2018 Q4 | 95.13 Million USD | 13.28% |
| 2018 FY | 314.75 Million USD | 66.6% |
| 2018 Q2 | 72.88 Million USD | 16.14% |
| 2018 Q3 | 83.98 Million USD | 15.23% |
| 2017 FY | 188.92 Million USD | 8.95% |
| 2017 Q4 | 65.35 Million USD | 48.25% |
| 2017 Q1 | 35.96 Million USD | -46.36% |
| 2017 Q2 | 43.51 Million USD | 20.98% |
| 2017 Q3 | 44.08 Million USD | 1.31% |
| 2016 FY | 173.4 Million USD | 47.58% |
| 2016 Q4 | 67.05 Million USD | 80.49% |
| 2016 Q3 | 37.14 Million USD | 2.81% |
| 2016 Q2 | 36.13 Million USD | 9.27% |
| 2016 Q1 | 33.06 Million USD | 1.46% |
| 2015 Q3 | 30.24 Million USD | 8.2% |
| 2015 Q2 | 27.95 Million USD | 4.67% |
| 2015 Q1 | 26.7 Million USD | 15.78% |
| 2015 FY | 117.49 Million USD | 34.49% |
| 2015 Q4 | 32.59 Million USD | 7.75% |
| 2014 FY | 87.36 Million USD | 31.35% |
| 2014 Q3 | 23.4 Million USD | 2.58% |
| 2014 Q2 | 22.81 Million USD | 26.2% |
| 2014 Q1 | 18.07 Million USD | 15.94% |
| 2014 Q4 | 23.06 Million USD | -1.44% |
| 2013 Q2 | 19.76 Million USD | 38.16% |
| 2013 Q4 | 15.59 Million USD | -7.41% |
| 2013 FY | 66.51 Million USD | 56.73% |
| 2013 Q1 | 14.3 Million USD | -9.65% |
| 2013 Q3 | 16.84 Million USD | -14.81% |
| 2012 Q2 | 9.98 Million USD | 37.43% |
| 2012 Q3 | 9.35 Million USD | -6.31% |
| 2012 Q4 | 15.83 Million USD | 69.34% |
| 2012 FY | 42.43 Million USD | 5.71% |
| 2012 Q1 | 7.26 Million USD | -29.29% |
| 2011 Q1 | 9.01 Million USD | 17.84% |
| 2011 FY | 40.14 Million USD | 167.41% |
| 2011 Q2 | 11.45 Million USD | 27.01% |
| 2011 Q3 | 9.4 Million USD | -17.87% |
| 2011 Q4 | 10.27 Million USD | 9.23% |
| 2010 Q1 | 2.18 Million USD | 1.63% |
| 2010 Q2 | 2.77 Million USD | 27.39% |
| 2010 Q3 | 2.4 Million USD | -13.4% |
| 2010 Q4 | 7.65 Million USD | 218.13% |
| 2010 FY | 15.01 Million USD | -21.18% |
| 2009 Q1 | 9.31 Million USD | 41.23% |
| 2009 Q3 | 3.23 Million USD | -25.47% |
| 2009 Q4 | 2.14 Million USD | -33.78% |
| 2009 FY | 19.04 Million USD | -27.05% |
| 2009 Q2 | 4.34 Million USD | -53.35% |
| 2008 Q2 | 7.08 Million USD | -0.45% |
| 2008 Q4 | 6.59 Million USD | 10.74% |
| 2008 Q1 | 7.11 Million USD | 29.69% |
| 2008 FY | 26.11 Million USD | -4.68% |
| 2008 Q3 | 5.95 Million USD | -15.9% |
| 2007 Q4 | 5.48 Million USD | -1.6% |
| 2007 Q3 | 5.57 Million USD | 15.09% |
| 2007 Q2 | 4.84 Million USD | -57.83% |
| 2007 Q1 | 11.48 Million USD | -45.48% |
| 2007 FY | 27.39 Million USD | -49.16% |
| 2006 Q3 | 12.31 Million USD | 29.52% |
| 2006 Q2 | 9.51 Million USD | -13.33% |
| 2006 Q4 | 21.07 Million USD | 71.04% |
| 2006 Q1 | 10.97 Million USD | 54.83% |
| 2006 FY | 53.87 Million USD | 95.44% |
| 2005 Q1 | 5.58 Million USD | -5.52% |
| 2005 FY | 27.56 Million USD | 0.01% |
| 2005 Q2 | 6.97 Million USD | 25.07% |
| 2005 Q3 | 7.91 Million USD | 13.45% |
| 2005 Q4 | 7.08 Million USD | -10.48% |
| 2004 Q2 | 9.08 Million USD | 85.64% |
| 2004 Q1 | 4.89 Million USD | 93.44% |
| 2004 FY | 27.56 Million USD | 156.73% |
| 2004 Q4 | 5.9 Million USD | -23.01% |
| 2004 Q3 | 7.67 Million USD | -15.6% |
| 2003 Q2 | 3.34 Million USD | 41.64% |
| 2003 FY | 10.73 Million USD | -70.54% |
| 2003 Q1 | 2.36 Million USD | -87.33% |
| 2003 Q4 | 2.53 Million USD | 1.44% |
| 2003 Q3 | 2.49 Million USD | -25.46% |
| 2002 Q3 | 4.03 Million USD | -45.08% |
| 2002 Q4 | 18.65 Million USD | 362.09% |
| 2002 Q2 | 7.34 Million USD | 14.63% |
| 2002 Q1 | 6.41 Million USD | -37.75% |
| 2002 FY | 36.44 Million USD | -9.97% |
| 2001 Q4 | 10.29 Million USD | 13.93% |
| 2001 FY | 40.48 Million USD | 29.91% |
| 2001 Q2 | 9.69 Million USD | -15.26% |
| 2001 Q1 | 11.44 Million USD | 127.26% |
| 2001 Q3 | 9.04 Million USD | -6.78% |
| 2000 Q1 | 11.53 Million USD | 0.0% |
| 2000 FY | 31.16 Million USD | 250.91% |
| 2000 Q2 | 55.69 Million USD | 382.95% |
| 2000 Q4 | -41.98 Million USD | -809.51% |
| 2000 Q3 | 5.91 Million USD | -89.38% |
| 1999 Q2 | 1.91 Million USD | 9.38% |
| 1999 Q1 | 1.74 Million USD | 0.0% |
| 1999 FY | 8.87 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -244.895% |
| Alkermes plc | 996.24 Million USD | 4.716% |
| Agenus Inc. | 78.18 Million USD | -1114.153% |
| Aptorum Group Limited | 10.56 Thousand USD | -8984009.408% |
| Ardelyx, Inc. | 169.93 Million USD | -458.596% |
| Dyadic International, Inc. | 9.15 Million USD | -10271.381% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -4165.766% |
| Lantern Pharma Inc. | 17.87 Million USD | -5209.788% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -14000.845% |
| Novavax, Inc. | 779.12 Million USD | -21.837% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -1071.031% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -1054.875% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -4788.432% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -3106.313% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -1686.798% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -149.48% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3805.362% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -2406.697% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -2984.921% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -1020.522% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -5337.71% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -463.574% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -2801.608% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -494.079% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 47.265% |
| AlloVir, Inc. | 180.93 Million USD | -424.648% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -112.964% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -3098.103% |
| Bicycle Therapeutics plc | 216.92 Million USD | -337.605% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -452.211% |
| ChromaDex Corporation | 56.37 Million USD | -1583.714% |
| Chimerix, Inc. | 93.38 Million USD | -916.459% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -6724.482% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -530.587% |
| CRISPR Therapeutics AG | 463.49 Million USD | -104.805% |
| Precision BioSciences, Inc. | 92.46 Million USD | -926.639% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -273.66% |
| Fortress Biotech, Inc. | 200.19 Million USD | -374.168% |
| Fortress Biotech, Inc. | 200.19 Million USD | -374.168% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -2798.861% |
| ImmuCell Corporation | 9.61 Million USD | -9770.285% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -501.506% |
| Immix Biopharma, Inc. | 16.14 Million USD | -5781.013% |
| Incyte Corporation | 1.19 Billion USD | 20.263% |
| Innoviva, Inc. | 132.15 Million USD | -618.299% |
| IO Biotech, Inc. | 91.44 Million USD | -938.09% |
| Jaguar Health, Inc. | 42.01 Million USD | -2159.338% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -460.774% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -1025.744% |
| ContextLogic Inc. | 387 Million USD | -145.287% |
| MiMedx Group, Inc. | 229.72 Million USD | -313.213% |
| MEI Pharma, Inc. | 34.78 Million USD | -2628.938% |
| NextCure, Inc. | 67.63 Million USD | -1303.464% |
| Onconetix, Inc. | 34.9 Million USD | -2619.367% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -7347.521% |
| Opthea Limited | 191.96 Million USD | -394.491% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -34398.698% |
| Vaxcyte, Inc. | 468.04 Million USD | -102.816% |
| PDS Biotechnology Corporation | 43.04 Million USD | -2105.264% |
| Precigen, Inc. | 84.18 Million USD | -1027.643% |
| Pharming Group N.V. | 225.49 Million USD | -320.975% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -465.619% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -1208.135% |
| PureTech Health plc | 144.59 Million USD | -556.487% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -628.726% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -287.204% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3805.362% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -315.105% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -2976.124% |
| Acelyrin, Inc. | 422.06 Million USD | -124.909% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -7361936.606% |
| Summit Therapeutics Inc. | 87.68 Million USD | -982.568% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -2461.14% |
| Senti Biosciences, Inc. | 94.7 Million USD | -902.335% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -668.303% |
| Elevation Oncology, Inc. | 45.44 Million USD | -1988.813% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -3121.219% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -23980.402% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -618.185% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -2684.982% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -11132.529% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -423.583% |
| Seer, Inc. | 110.49 Million USD | -759.137% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -1244.677% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -915.491% |
| ESSA Pharma Inc. | 32.13 Million USD | -2854.061% |
| GlycoMimetics, Inc. | 39.28 Million USD | -2316.327% |
| GT Biopharma, Inc. | 13.57 Million USD | -6892.199% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -331.816% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -371.999% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -265.91% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -1572.441% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -1655.29% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -9452.173% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -135.22% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -4914.85% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -1772.568% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -265.58% |
| Aptose Biosciences Inc. | 52.35 Million USD | -1713.089% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -6487.345% |
| Soligenix, Inc. | 7.79 Million USD | -12077.427% |
| Century Therapeutics, Inc. | 56.07 Million USD | -1592.962% |
| Kura Oncology, Inc. | 165.8 Million USD | -472.52% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -728.998% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -11310.759% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -38151.373% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -781.41% |
| Autolus Therapeutics plc | 196.72 Million USD | -382.53% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -1021.302% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -715.145% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -4797.389% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -195.023% |
| GRI Bio, Inc. | 11.33 Million USD | -8278.297% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -13353.816% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -623.561% |
| IGM Biosciences, Inc. | 265.59 Million USD | -257.415% |
| INmune Bio, Inc. | 29.89 Million USD | -3075.211% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -450.124% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -2254.65% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -5840.544% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -5930.288% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -1428.65% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -782.853% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -244.318% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -214.897% |
| Verastem, Inc. | 92.08 Million USD | -930.864% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -5191.605% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -411.111% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -681.883% |
| Histogen Inc. | 14.27 Million USD | -6551.212% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -5815.084% |
| Surrozen, Inc. | 18.55 Million USD | -5017.31% |
| Organovo Holdings, Inc. | 14.91 Million USD | -6264.472% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -18548.664% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -1490.767% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -3601.256% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -1919.446% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -12336.532% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -432.886% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -1859.342% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -287.447% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -6077.441% |
| Apollomics, Inc. | 54.14 Million USD | -1653.345% |
| Amarin Corporation plc | 272.35 Million USD | -248.536% |
| Mesoblast Limited | 5.9 Million USD | -15983.717% |
| Turnstone Biologics Corp. | 78.33 Million USD | -1111.75% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -288.847% |
| Synaptogenix, Inc. | 8.31 Million USD | -11317.821% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -6408.028% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -275.119% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -2748.061% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -10648.904% |
| Exelixis, Inc. | 1.58 Billion USD | 40.177% |
| Better Therapeutics, Inc. | 38.26 Million USD | -2380.95% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -309.076% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | -10.998% |
| NLS Pharmaceutics AG | 11.8 Million USD | -7939.772% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -11703.931% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -3064.942% |
| Gritstone bio, Inc. | 148.37 Million USD | -539.776% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1278.518% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -5702.252% |
| Avid Bioservices, Inc. | 25.99 Million USD | -3551.566% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -5950.184% |
| MediWound Ltd. | 18.86 Million USD | -4931.063% |
| OmniAb, Inc. | 83.89 Million USD | -1031.487% |
| Alector, Inc. | 248.8 Million USD | -281.533% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -305.134% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -1716.733% |
| Zai Lab Limited | 547.47 Million USD | -73.389% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -138.117% |
| Aura Biosciences, Inc. | 84.99 Million USD | -1016.896% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -284.102% |
| Immunic, Inc. | 99.22 Million USD | -856.695% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -496.974% |
| Veracyte, Inc. | 357.93 Million USD | -165.206% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 89.471% |
| FibroGen, Inc. | 398.11 Million USD | -138.44% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -6580.232% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -13681.479% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -13221.593% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 70.842% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -3568.925% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -199.884% |
| TG Therapeutics, Inc. | 198.47 Million USD | -378.277% |
| Galecto, Inc. | 35.62 Million USD | -2564.443% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -2232.967% |
| Fortrea Holdings Inc. | 457.3 Million USD | -107.579% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -1648.887% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -3187.142% |
| XBiotech Inc. | 37.51 Million USD | -2430.688% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1278.518% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -4497.128% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -568.207% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -858.124% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -757.384% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 0.938% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -3190.903% |
| Vaxxinity, Inc. | 56.05 Million USD | -1593.567% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -120.43% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -4155.19% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -756.216% |
| NexImmune, Inc. | 28.16 Million USD | -3270.056% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -17062.718% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -5205.354% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 66.282% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -3628.587% |
| Scopus BioPharma Inc. | 11.71 Million USD | -8003.039% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -647.085% |
| Ainos, Inc. | 12.95 Million USD | -7228.694% |
| Pluri Inc. | 22.48 Million USD | -4122.691% |
| Prothena Corporation plc | 282.4 Million USD | -236.133% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -374.578% |
| Celularity Inc. | 215.05 Million USD | -341.398% |
| Rallybio Corporation | 78.93 Million USD | -1102.631% |
| Cue Biopharma, Inc. | 19.54 Million USD | -4757.543% |
| MeiraGTx Holdings plc | 151.07 Million USD | -528.325% |
| Omeros Corporation | 94.75 Million USD | -901.848% |
| Humacyte, Inc. | 23.49 Million USD | -3939.924% |
| Immunocore Holdings plc | 308.04 Million USD | -208.162% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -27901.799% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -992.8% |
| Blueprint Medicines Corporation | 722.86 Million USD | -31.32% |
| CalciMedica, Inc. | 21.81 Million USD | -4251.015% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -1171.445% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -491.293% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -454.167% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -221.849% |
| Pulmatrix, Inc. | 22.03 Million USD | -4207.383% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -2645.513% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -968.194% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -72.103% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -1208.405% |
| Cytokinetics, Incorporated | 173.61 Million USD | -446.772% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -2657.956% |
| Nutriband Inc. | 5.73 Million USD | -16454.863% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -2076.555% |
| Vor Biopharma Inc. | 126.03 Million USD | -653.167% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 20.175% |
| Evogene Ltd. | 27.79 Million USD | -3315.837% |
| ProKidney Corp. | 151.52 Million USD | -526.484% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -1179.759% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -12240.498% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -54.546% |
| CorMedix Inc. | 48.95 Million USD | -1838.938% |
| BioLineRx Ltd. | 50.8 Million USD | -1768.55% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -529.901% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -2393.331% |
| Atai Life Sciences N.V. | 125.78 Million USD | -654.669% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -1062.75% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -1066.039% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -275.868% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -2799.392% |
| MediciNova, Inc. | 10.9 Million USD | -8608.605% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -636.889% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -12976.078% |
| GeoVax Labs, Inc. | 6.02 Million USD | -15662.765% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -99.274% |
| Biomea Fusion, Inc. | 126.13 Million USD | -652.575% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 27.639% |
| Mereo BioPharma Group plc | 35.84 Million USD | -2548.46% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -396.764% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -312.805% |
| Absci Corporation | 73.66 Million USD | -1188.601% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -3341.596% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -610.578% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -291.994% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -262.247% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -356.389% |
| Allakos Inc. | 196.05 Million USD | -384.179% |
| Imunon, Inc. | 20.31 Million USD | -4573.762% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -736.582% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -157.523% |
| BioAtla, Inc. | 129.68 Million USD | -631.963% |
| NLS Pharmaceutics AG | 11.8 Million USD | -7939.772% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -5891.675% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -1017.856% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -2173.243% |
| XOMA Corporation | 46.46 Million USD | -1943.047% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -753.875% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -566.321% |
| aTyr Pharma, Inc. | 12.97 Million USD | -7213.822% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -815.78% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -449.118% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -272.604% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -2437.588% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -11441.428% |
| Akari Therapeutics, Plc | 16.8 Million USD | -5548.346% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -41644.658% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -217.141% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -14007.58% |
| UroGen Pharma Ltd. | 138.88 Million USD | -583.472% |
| Sutro Biopharma, Inc. | 243 Million USD | -290.628% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -12948.939% |
| Orgenesis Inc. | 45.75 Million USD | -1974.57% |
| Entera Bio Ltd. | 8.86 Million USD | -10614.007% |
| GH Research PLC | 41.22 Million USD | -2202.802% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -3592.473% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -1042.958% |
| Xencor, Inc. | 306.97 Million USD | -209.229% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -19140.714% |
| Replimune Group, Inc. | 234.77 Million USD | -304.331% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -4532.827% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -394.933% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -14007.58% |
| Portage Biotech Inc. | 18.19 Million USD | -5116.006% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -12976.078% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -804.394% |
| OncoCyte Corporation | 25.63 Million USD | -3602.699% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -15472.871% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -8185.38% |
| Purple Biotech Ltd. | -22.46 Million USD | 4325.135% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -5660.079% |
| scPharmaceuticals Inc. | 65.17 Million USD | -1356.413% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -11130.222% |
| HilleVax, Inc. | 133.34 Million USD | -611.883% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -9129.567% |
| Tharimmune, Inc. | 9.45 Million USD | -9939.544% |
| Genprex, Inc. | 31.06 Million USD | -2956.161% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -406.202% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -2925.34% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -123986.405% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -17327.485% |
| OKYO Pharma Limited | 8243.57 USD | -11515068.792% |
| Savara Inc. | 15.74 Million USD | -5928.968% |
| Curis, Inc. | 58.35 Million USD | -1526.7% |
| Daré Bioscience, Inc. | 33.6 Million USD | -2724.391% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -18540.417% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -12622.973% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -3412.919% |
| BeiGene, Ltd. | 3.28 Billion USD | 71.117% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -4660.754% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -90.322% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -517.799% |
| Erasca, Inc. | 141.52 Million USD | -570.737% |
| bluebird bio, Inc. | 240.23 Million USD | -295.143% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -20868.996% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 45.641% |
| DBV Technologies S.A. | 92.16 Million USD | -930.014% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -20868.996% |
| Moderna, Inc. | 6.39 Billion USD | 85.154% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -2127.842% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -6507.692% |
| Molecular Templates, Inc. | 63.09 Million USD | -1404.59% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -1323.159% |
| Travere Therapeutics, Inc. | 472 Million USD | -101.114% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -562.378% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -1429.044% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -2086.532% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -356.09% |
| MacroGenics, Inc. | 217.21 Million USD | -337.014% |
| RenovoRx, Inc. | 11.39 Million USD | -8229.774% |
| Adicet Bio, Inc. | 152.03 Million USD | -524.358% |
| Prime Medicine, Inc. | 186.63 Million USD | -408.608% |
| Aditxt, Inc. | 25.95 Million USD | -3557.931% |
| Adagene Inc. | 41.83 Million USD | -2169.257% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -12885.613% |
| Quantum-Si incorporated | 111.65 Million USD | -750.143% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -452.378% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -6411.703% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -2549.939% |
| SciSparc Ltd. | 9.01 Million USD | -10434.469% |
| Vericel Corporation | 142.04 Million USD | -568.305% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -10865.668% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -4011.385% |
| Generation Bio Co. | 144.46 Million USD | -557.078% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -1043.275% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -997.919% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -221.0% |
| Invivyd, Inc. | 205.75 Million USD | -361.355% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -1215.513% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -10021.668% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -1161.409% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -9127.773% |
| 2seventy bio, Inc. | 289.88 Million USD | -227.459% |
| ADMA Biologics, Inc. | 66.58 Million USD | -1325.616% |
| Clene Inc. | 41.07 Million USD | -2211.156% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -7311.535% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -1632.355% |
| GeoVax Labs, Inc. | 6.02 Million USD | -15662.765% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -169.64% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -2484.288% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -2714.46% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -815.374% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -2812.826% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -457.477% |
| Vir Biotechnology, Inc. | 767.72 Million USD | -23.647% |
| Evaxion Biotech A/S | 22.27 Million USD | -4162.51% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -600.334% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -304.144% |
| Trevena, Inc. | 38.41 Million USD | -2371.197% |
| Surrozen, Inc. | 18.55 Million USD | -5017.31% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -1087.393% |
| Cingulate Inc. | 22.75 Million USD | -4070.891% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 12770.328% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -2025.195% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -11428.635% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -825.585% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | -25.882% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -1429.241% |
| Clearmind Medicine Inc. | 8.74 Million USD | -10759.432% |
| Kronos Bio, Inc. | 128.11 Million USD | -640.927% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -1029.105% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -32265.014% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -841.475% |
| Statera Biopharma, Inc. | 28.82 Million USD | -3192.672% |
| ImmunityBio, Inc. | 362.87 Million USD | -161.597% |
| Korro Bio, Inc. | 84.53 Million USD | -1022.934% |
| Kineta, Inc. | 21.15 Million USD | -4386.959% |
| BioVie Inc. | 31.95 Million USD | -2871.064% |
| Codexis, Inc. | 66.51 Million USD | -1327.074% |
| Celularity Inc. | 215.05 Million USD | -341.398% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -318.876% |
| Celcuity Inc. | 66.23 Million USD | -1333.272% |
| Virax Biolabs Group Limited | 6.54 Million USD | -14399.036% |
| Cibus, Inc. | 320.3 Million USD | -196.362% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -2107.584% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -2704.813% |
| IN8bio, Inc. | 30.33 Million USD | -3029.054% |
| Kodiak Sciences Inc. | 277.32 Million USD | -242.297% |
| Annexon, Inc. | 143.72 Million USD | -560.48% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -643.987% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -4043.616% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -148222.031% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -21.765% |
| Eyenovia, Inc. | 25.4 Million USD | -3636.3% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -576.521% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -16966.9% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -1099.577% |
| Arcellx, Inc. | 200.19 Million USD | -374.159% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -1968.107% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -338.638% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -9433.604% |
| Moolec Science SA | 52.75 Million USD | -1699.526% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -1452.653% |
| Geron Corporation | 70.44 Million USD | -1247.597% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -1939.667% |
| Royalty Pharma plc | 862.4 Million USD | -10.071% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -909.079% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -10076.615% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -4094.974% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -356.788% |
| Humacyte, Inc. | 23.49 Million USD | -3939.924% |
| Structure Therapeutics Inc. | 102.77 Million USD | -823.63% |
| 89bio, Inc. | 151.2 Million USD | -527.802% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -1084.622% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -6428.618% |
| Genelux Corporation | 24.33 Million USD | -3800.805% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -2698.281% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -449.122% |
| Notable Labs, Ltd. | 14.77 Million USD | -6326.953% |
| Liquidia Corporation | 87.98 Million USD | -978.902% |
| Mustang Bio, Inc. | 48.5 Million USD | -1857.199% |
| Immunovant, Inc. | 282.7 Million USD | -235.773% |
| Quantum-Si incorporated | 111.65 Million USD | -750.143% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -4110.704% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -4363.54% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -830.539% |
| Acasti Pharma Inc. | 11.3 Million USD | -8299.796% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -4041.428% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -5840.544% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -1939.579% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -83566.291% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -5875.456% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -3155.688% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -2193.787% |
| PepGen Inc. | 84.76 Million USD | -1019.861% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -3103.608% |
| United Therapeutics Corporation | 885.1 Million USD | -7.249% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -4045.788% |
| Solid Biosciences Inc. | 104.31 Million USD | -809.995% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -2800.674% |
| Immuneering Corporation | 58.41 Million USD | -1525.088% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -18548.664% |
| Silo Pharma, Inc. | 3.92 Million USD | -24104.382% |
| Belite Bio, Inc | 31.66 Million USD | -2897.54% |
| XOMA Corporation | 46.46 Million USD | -1943.047% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -1305.272% |
| Bionomics Limited | 17.89 Billion USD | 94.695% |
| Apogee Therapeutics, Inc. | 93 Million USD | -920.678% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2760.485% |
| uniQure N.V. | 285.08 Million USD | -232.974% |
| Cassava Sciences, Inc. | 105.95 Million USD | -795.893% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -12885.613% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -388.788% |
| Forte Biosciences, Inc. | 32.47 Million USD | -2822.872% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -11324.828% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -3129.328% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -16966.9% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -6580.232% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -10579.053% |
| Altimmune, Inc. | 30.55 Million USD | -3006.627% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -121.971% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2760.485% |
| Compugen Ltd. | 43.97 Million USD | -2058.834% |
| Peak Bio, Inc. | 1249.13 USD | -75993671.665% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -1180.708% |
| Benitec Biopharma Inc. | 22.38 Million USD | -4141.18% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -290.339% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -3225.723% |
| Zura Bio Limited | 62.63 Million USD | -1415.471% |
| PolyPid Ltd. | 21.04 Million USD | -4410.625% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -5732.275% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -3225.723% |
| Instil Bio, Inc. | 85.78 Million USD | -1006.558% |
| argenx SE | 1.53 Billion USD | 38.1% |
| Immunome, Inc. | 122.82 Million USD | -672.888% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -1858.329% |
| Verona Pharma plc | 67.15 Million USD | -1313.616% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -3567.224% |
| Shattuck Labs, Inc. | 93.61 Million USD | -914.016% |
| CervoMed Inc. | 14.95 Million USD | -6246.275% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -1242.604% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -11010.265% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -1761.296% |
| Moolec Science SA | 52.75 Million USD | -1699.526% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -5671.131% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -616.125% |
| AnaptysBio, Inc. | 181.56 Million USD | -422.813% |
| Design Therapeutics, Inc. | 78.19 Million USD | -1114.044% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -990.591% |
| NeurAxis, Inc. | 8.82 Million USD | -10661.133% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -7442.797% |
| Lumos Pharma, Inc. | 38.66 Million USD | -2355.091% |
| Achilles Therapeutics plc | 75.25 Million USD | -1161.393% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -3567.224% |
| 180 Life Sciences Corp. | 13.47 Million USD | -6943.302% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -3481.787% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -32265.014% |
| Nutriband Inc. | 5.73 Million USD | -16454.863% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -756.888% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -1605.678% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -1765.723% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -1336.12% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -1653.893% |
| Palisade Bio, Inc. | 13.32 Million USD | -7026.584% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -1990.469% |
| Beam Therapeutics Inc. | 554.19 Million USD | -71.287% |
| Neurogene Inc. | 55.58 Million USD | -1607.826% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -282.013% |
| AEON Biopharma, Inc. | 48.42 Million USD | -1860.109% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -881.554% |
| Sesen Bio, Inc. | 78.38 Million USD | -1111.086% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -1036.445% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -7441.661% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -110.482% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -980.056% |
| Athira Pharma, Inc. | 125.46 Million USD | -656.588% |
| Vaccinex, Inc. | 23.45 Million USD | -3947.158% |
| HCW Biologics Inc. | 21.02 Million USD | -4414.374% |
| XOMA Corporation | 46.46 Million USD | -1943.047% |
| Nektar Therapeutics | 190.9 Million USD | -397.248% |
| Arvinas, Inc. | 480 Million USD | -97.763% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -41644.658% |
| Merus N.V. | 200.49 Million USD | -373.461% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -818.447% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -2641.944% |
| Rezolute, Inc. | 70.38 Million USD | -1248.631% |
| Clene Inc. | 41.07 Million USD | -2211.156% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -5695.784% |
| BeyondSpring Inc. | 24.86 Million USD | -3717.659% |
| Synlogic, Inc. | 58.53 Million USD | -1521.781% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -5205.505% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -21032.257% |
| Peak Bio, Inc. | 1249.13 USD | -75993671.665% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -1470.428% |
| Krystal Biotech, Inc. | 160.42 Million USD | -491.713% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -250.758% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -172.746% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -43913.819% |
| MannKind Corporation | 125.59 Million USD | -655.799% |
| Ikena Oncology, Inc. | 84.57 Million USD | -1022.363% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -9739.961% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -959.431% |
| Gossamer Bio, Inc. | 183.75 Million USD | -416.579% |
| CohBar, Inc. | 12.38 Million USD | -7562.562% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -1771.424% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -3341.596% |
| Legend Biotech Corporation | 583.14 Million USD | -62.783% |
| Mural Oncology plc | 192.07 Million USD | -394.224% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -1313.706% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -5779.499% |
| Disc Medicine, Inc. | 91.12 Million USD | -941.713% |
| Champions Oncology, Inc. | 28.11 Million USD | -3276.951% |
| REGENXBIO Inc. | 321.15 Million USD | -195.575% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -17606.017% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1602.527% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -2336.461% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -730.086% |
| Vaxart, Inc. | 90.72 Million USD | -946.294% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -11041.551% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -2118.206% |
| Cellectis S.A. | 97.32 Million USD | -875.402% |
| Longeveron Inc. | 21.25 Million USD | -4367.111% |
| Repare Therapeutics Inc. | 167.35 Million USD | -467.207% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 30.243% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -1154.889% |
| Revolution Medicines, Inc. | 498.76 Million USD | -90.322% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -14170.31% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -2059.669% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -1172.638% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -1263.195% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -8482.83% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 80.12% |
| Denali Therapeutics Inc. | 527.23 Million USD | -80.047% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -10865.668% |
| Veru Inc. | 101.34 Million USD | -836.634% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -3955.458% |
| Cingulate Inc. | 22.75 Million USD | -4070.891% |
| Passage Bio, Inc. | 108.38 Million USD | -775.791% |
| Context Therapeutics Inc. | 25.07 Million USD | -3686.047% |
| Exicure, Inc. | 14.07 Million USD | -6643.826% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -360.663% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -2092.238% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -10243.587% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -275.97% |
| Nuvalent, Inc. | 149.49 Million USD | -534.991% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -11667.355% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -815.833% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -4325.666% |
| OmniAb, Inc. | 83.89 Million USD | -1031.487% |
| Anew Medical, Inc. | 1.3 Million USD | -72872.869% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -2797.268% |
| Lipocine Inc. | 15.08 Million USD | -6194.776% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -1285.52% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -1146.535% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -2254.65% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -726.573% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -4140.801% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -42.93% |
| Ocugen, Inc. | 71.56 Million USD | -1226.395% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -911.294% |
| Q32 Bio Inc. | 92.68 Million USD | -924.235% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -4383.144% |
| Alumis Inc. Common Stock | 158.17 Million USD | -500.137% |
| Equillium, Inc. | 50.6 Million USD | -1775.787% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -1421.105% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -6726.488% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -4931.834% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -1921.812% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -775.169% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -7559.823% |
| Dominari Holdings Inc. | 23.83 Million USD | -3882.635% |
| Edesa Biotech, Inc. | 9.22 Million USD | -10192.594% |
| vTv Therapeutics Inc. | 11.9 Million USD | -7872.294% |
| Bio-Techne Corporation | 563.03 Million USD | -68.596% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -132.203% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -253.206% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -617.631% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -6487.058% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -479.893% |
| Nkarta, Inc. | 131.65 Million USD | -621.049% |
| BioCardia, Inc. | 12.12 Million USD | -7731.54% |
| Iterum Therapeutics plc | 47.46 Million USD | -1899.791% |